5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Mankind Pharma Ltd.

•
mankindpharma.comBSE: 543904NSE: MANKIND
Market Cap₹ 94,050 Cr.
Current Price
High / Low₹ 2,674 / 1,910
Stock P/E46.0
Book Value₹ 407
Price to Book5.09
Dividend Yield0.04 %
ROCE13.2 %
ROE12.7 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2019 • Pharmaceutical Products: 99.9% • Others: 0.1%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has consistently been profitable over the last 5 years
  • Latest quarter profit grew 29.1% YoY, showing strong momentum
  • Company has delivered good sales growth of 18.1% CAGR over last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.31x)
  • Working capital cycle has improved - days down from 38 to 11
  • Company generates healthy free cash flow

CONS

  • Promoter holding has decreased over last 2 years: -2.2pp
  • Company has delivered a poor profit growth of 8.4% over past five years
  • Stock is trading at 5.1x its book value
  • Though reporting repeated profits, the company pays out little dividend (2.2%)
  • Expensive relative to growth - PEG of 3.3

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100NIFTY MIDCAP 150
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,5792,7082,6072,4222,8683,0613,1993,0793,5703,6973,5673,4434,031
1,9242,0252,0001,8362,1962,2142,3832,3962,7242,7762,6482,5133,310
Operating Profit655683606586672847816683847921919930721
OPM %25.39%25.21%23.26%24.20%23.42%27.67%25.51%22.19%23.72%24.92%25.77%27.01%17.88%
5960709299109772518092-349145
Interest6999117221191171170157142110
Depreciation8796110100103100187231219222223223226
Profit before Tax620638558570657849485513537622506656769
Tax %21.02%20.36%18.38%16.68%18.69%22.39%22.78%16.85%17.84%16.70%18.81%15.20%25.39%
Net Profit0000543659385425445520414559574
12.1512.5111.3311.7713.2816.379.2910.2010.6212.399.9013.4413.76

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
4,3824,9214,9805,8726,2147,7828,74910,26012,20714,27814,738
3,5313,9274,0554,4274,5655,7916,8487,7459,18710,65511,247
Operating Profit8519949251,4451,6491,9911,9022,5153,0203,6223,491
OPM %19.42%20.19%18.57%24.60%26.54%25.58%21.74%24.51%24.74%25.37%23.69%
897253104171196129280537229194
Interest425442321604634432644579
Depreciation31466999119167326378621886893
Profit before Tax9069958751,4381,6921,9751,6712,3982,5162,3332,553
Tax %31.99%32.46%30.20%26.54%23.56%26.42%21.63%19.06%20.26%16.92%19.35%
Net Profit6166726101,0561,2931,4531,3101,9412,0071,9382,059
EPS15.7016.8714.4425.7231.5935.7832.0047.7548.2546.34—
Dividend Payout %0.00%26.54%30.81%12.05%0.00%0.00%0.00%0.00%0.00%2.16%—

COMPOUNDED SALES GROWTH

10 Years:
14%
5 Years:
18%
3 Years:
18%

COMPOUNDED PROFIT GROWTH

10 Years:
13%
5 Years:
9%
3 Years:
14%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
9%
1 Year:
-12%

RETURN ON EQUITY

10 Years:
23%
5 Years:
20%
3 Years:
18%
Last Year:
13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2025

Aug 8

₹ 1

Rs.1.0000 per share(100%)Interim Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital20404040404040404141
Minority Interest98134159186141161188213236261
2,9072,8412,7833,4454,6826,1157,3959,30014,24716,211
314262811272879021932078,0733,562
Trade Payables4926495627456671,0761,0087771,1331,341
1932712594825078148611,3463,9206,339
Total Liabilities3,7414,3604,0845,0256,3249,1089,68611,88327,65227,755
7931,0141,3991,5941,6593,5834,2454,54019,00418,620
Capital Work in Progress302482327313372670493207306655
9497897598291,5121,1091,3462,5682,0421,985
7897898218991,1841,7601,4981,5532,0942,144
00000008481,5381,730
Cash & Bank146139141420701406453708554483
7621,1476369708971,5801,6491,4582,1132,138
Total Assets3,7414,3604,0845,0256,3249,1089,68611,88327,65227,755

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
9149639421,4031,5911,4192,1362,1522,4133,121
Cash from Investing-625-505-444-439-1,222-1,369-1,054-2,082-12,683-196
Cash from Financing2-89-175-527-8605-740510,233-2,953
546-19106-931551976-37-28

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
74.8774.8772.7172.7072.6872.6772.6672.6672.63
11.5812.3713.3412.9213.0712.8311.3410.249.45
9.949.9111.0511.4411.4611.8713.2214.4215.35
Government0.000.000.000.000.000.000.000.000.00
3.612.862.902.932.792.612.792.682.57

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Mankind Pharma Limited has informed the Exchange about Schedule of meet

2026-09-07
General Updates

2026-09-07 - Update on Voluntary Liquidation of Bharat Serums and Vaccines Limited, a WOS.

2026-09-01
ESOP/ESOS/ESPS

2026-09-01 - Mankind Pharma Limited has informed the Exchange regarding Allotment of 49112 Shares.

2026-08-31
General Updates

2026-08-31 - Mankind Pharma Limited has informed the Exchange about General Updates

2026-08-30
Cessation

2026-08-30 - Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Bharat Anand as Non- Executive Independent Director of the company w.e.f. August 30, 2026.

2026-08-26
Other Restructuring

2026-08-26 - Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation.

2026-08-26
Outcome of Board Meeting

2026-08-26 - Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation.

2026-08-22
General Updates

2026-08-22 - Mankind Pharma Limited has informed the Exchange about General Updates

2026-08-20
Press Release

2026-08-20 - Mankind Pharma Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India".

News

Recent coverage and analyst commentary for MANKIND

Loading news…

🤖

AI Stock Analyst

Mankind Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login